Literature DB >> 33530275

The efficacy and safety of Xiangsha Liujunzi decoction in the treatment of chronic non-atrophic gastritis: A protocol for a systematic review and meta-analysis.

Pan Yue1,2, Juan Zhong1,2, Jiajun Huang3, Zhaoxi Lan3, Sen Zhong1,2.   

Abstract

BACKGROUND: Chronic non-atrophic gastritis is the most common type of chronic gastritis. Even if treated with current standard pharmacotherapy, the efficacy is not very satisfactory due to many factors. Traditional Chinese Medicine decoctions are increasingly used in the treatment of chronic gastritis, and many studies have shown that Xiangsha Liujunzi decoction is effective and safe in the treatment of chronic non-atrophic gastritis. However, it is controversy if Xiangsha Liujunzi decoction can provide an evidence-based clinical efficacy and safety in the treatment of chronic non-atrophic gastritis.
METHODS: We will go through 8 databases, and conduct a systematic review of Xiangsha Liujunzi decoction and health-related outcomes in chronic non-atrophic gastritis patients according to the Preferred Reporting Items for Systematic Reviews. The primary objective is to assess the impact of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines on clinical outcomes relevant to chronic non-atrophic gastritis patients, such as clinical effective rate,Helicobacter pylori eradication rate, efficacy under endoscopy, 1-year recurrent rate, and number of reported adverse events. Cochrane Risk Assessment Tool will be used to assess the quality of eligible studies according to the Cochrane handbook.
RESULTS: The results of this systematic review will provide a synthesis of current evidence of Xiangsha Liujunzi decoction and we have a specific opportunity to determine the efficacy and safety of it.
CONCLUSION: This study will explore whether or not Xiangsha Liujunzi decoction can be used as one of the complementary and alternative therapies in the treatment of chronic non-atrophic gastritis. REGISTRATION NUMBER: Identifier: DOI 10.17605/OSF.IO/TX27U (https://osf.io/tx27u/).
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33530275      PMCID: PMC7850646          DOI: 10.1097/MD.0000000000024504

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  10 in total

Review 1.  Helicobacter pylori treatment in the era of increasing antibiotic resistance.

Authors:  David Y Graham; Lori Fischbach
Journal:  Gut       Date:  2010-06-04       Impact factor: 23.059

Review 2.  Staging and grading of chronic gastritis.

Authors:  Massimo Rugge; Robert M Genta
Journal:  Hum Pathol       Date:  2005-03       Impact factor: 3.466

Review 3.  Current pharmacotherapy options for gastritis.

Authors:  Wouter J den Hollander; Ernst J Kuipers
Journal:  Expert Opin Pharmacother       Date:  2012-11-20       Impact factor: 3.889

4.  [Effects of Xiangsha Liujunzi decoction on TLR signal pathway in gastric mucosa tissues of rats with Helicobacter pylori-induced chronic atrophic gastritis].

Authors:  Zhi-Qiang Lin; Da-Xuan Wang; Shan-Shan Hong; Xin-Yang Fu
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2016-08

5.  Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer.

Authors:  Hiroshi Ohata; Shintaro Kitauchi; Noriko Yoshimura; Kouichi Mugitani; Masataka Iwane; Hideya Nakamura; Akiyoshi Yoshikawa; Kimihiko Yanaoka; Kenji Arii; Hideyuki Tamai; Yasuhito Shimizu; Tatsuya Takeshita; Osamu Mohara; Masao Ichinose
Journal:  Int J Cancer       Date:  2004-03       Impact factor: 7.396

6.  Chronic gastritis in China: a national multi-center survey.

Authors:  Yiqi Du; Yu Bai; Pei Xie; Jingyuan Fang; Xiaozhong Wang; Xiaohua Hou; Dean Tian; Chengdang Wang; Yandi Liu; Weihong Sha; Bangmao Wang; Yanqing Li; Guoliang Zhang; Yan Li; Ruihua Shi; Jianming Xu; Youming Li; Minghe Huang; Shengxi Han; Jie Liu; Xu Ren; Pengyan Xie; Zhangliu Wang; Lihong Cui; Jianqiu Sheng; Hesheng Luo; Zhaohui Wang; Xiaoyan Zhao; Ning Dai; Yuqiang Nie; Yiyou Zou; Bing Xia; Zhining Fan; Zhitan Chen; Sanren Lin; Zhao-Shen Li
Journal:  BMC Gastroenterol       Date:  2014-02-07       Impact factor: 3.067

Review 7.  Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer.

Authors:  Yo Han Park; Nayoung Kim
Journal:  J Cancer Prev       Date:  2015-03

8.  Efficacy of traditional Chinese medicine for chronic gastritis: A meta-analysis of randomized controlled trials.

Authors:  Zi-Xing Yan; Yun-Kai Dai; Teng Ma; Xiao-Ying Lin; Wen-Hui Chen; You-Mei Liu; Ruo-Zhen Zu; Xiao-Bin Zhang; Peng Jiang; Jian-Hua Yang; Sheng Li; Li-Sheng Zheng; Zhen-Wen Lin
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21

Review 10.  Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis.

Authors:  Zhong Li; Cong Wu; Ling Li; Zhaoming Wang; Haibin Xie; Xiaozhou He; Jin Feng
Journal:  Saudi J Gastroenterol       Date:  2017 Jul-Aug       Impact factor: 2.485

  10 in total
  1 in total

1.  Efficacy of Xiang-Sha-Liu-Jun-Zi on chemotherapy-induced nausea and vomiting: A protocol for systematic review and meta-analysis.

Authors:  Hang Xiao; Liangji Liu; Shiwen Ke; Yuqin Zhang; Wenqiang Zhang; Shaobin Xiong; Wei Zhang; Jiaqing Ouyang
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.